You are here

Article Text

Article menu

Download PDFPDF

XML
Inflammatory bowel disease
Combination therapy with vedolizumab and etanercept in a patient with pouchitis and spondylarthritis
  1. Johannes Bethge,
  2. Silvia Meffert,
  3. Mark Ellrichmann,
  4. Claudio Conrad,
  5. Susanna Nikolaus,
  6. Stefan Schreiber
  1. Medical Department I, Gastroenterology, University Medical Center, Schleswig Holstein, Campus Kiel, Kiel, Germany
  1. Correspondence to Professor Stefan Schreiber; s.schreiber{at}mucosa.de and Dr Johannes Bethge; johannes.bethge{at}uksh.de

Abstract

Inflammatory bowel disease is frequently associated with spondylarthritis (SpA). It has been discussed that α4/β7 expressing lymphocytes are involved in the aetiology of SpA. We report a case of a successful combination therapy of vedolizumab (VDZ) and etanercept (ETA) in a patient with ulcerative colitis with pouchitis and SpA. In our case VDZ was effective for pouchitis and ineffective for SpA. The combination with ETA might be a useful treatment strategy to control both diseases and first indications suggest that it is safe. α4/β7 Expressing lymphocytes are most likely not associated in the aetiology of SpA.

  • INFLAMMATORY BOWEL DISEASE
  • SPONDYLOARTHROPATHY
  • INTEGRINS
  • TNF-ALPHA

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

https://doi.org/10.1136/bmjgast-2016-000127

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text